Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Airbus Joins Air India A320 Altitude Drop Probe 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Orion Group purchased a controlling stake in LegoChem Biosciences, a South Korean research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines. The confectionery company is acquiring a 25.7% stake worth KRW550 billion or around $418 million.
With the size of its acquisition, the Orion Group has now become the largest shareholder of LegoChem Biosciences. The firm made the deal as it seeks to broaden its business and enter into new drug development business beyond antibody-drug conjugate platform technology, as per the Korea Joongang Daily.
What is Included in the Agreement
Pan Orion Corporation, the Hong Kong-headquartered subsidiary of the Orion Group, led the acquisition deal. Based on the reports, the agreement includes a combination of share purchases and rights offerings.
Moreover, it was stated in the electronic disclosure of the Financial Supervisory Service that Orion will buy 7.96 million units of new stakes at KRW59,000 per share. In addition, it will also purchase 1.4 million existing shares at the base rate of 56,186 per share. Orion is scheduled to settle the payment for the acquisition on March 29.
Orion's Venture Into Biotech Business
The Korea Economic Daily reported that this buyout deal not only marks the Orion Group's deeper venture into the biotech industry but is also expected to help the company in achieving its goal of giving a boost to LegoChem Biosciences by providing the needed financial push for clinical development and encouraging new technology research.
Once the deal is completed, Orion will be the largest shareholder in LegoChem Biosciences. Currently, the company's chief executive officer, Kim Yong Zu, holds the biggest share, and after the acquisition, he will still retain some of his shares and keep his CEO position. LegoChem is also set to become one of the confectionery giant's affiliates.
Photo by: Orion Website
